Stifel on Revance Therapeutic (RVNC): 'Daxxify Approved Offering an Innovative Product and Approach to Market Entry'
Tweet Send to a Friend
Stifel analyst Annabel Samimy reiterated a Buy rating on Revance Therapeutic (NASDAQ: RVNC)The analyst comments "We reiterate our Buy on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
